Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apelin-EV
- Development stage
- Preclinical
- Lead developer
- ShiftBio
- Modality
- Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Apelin-EV (also known as CAR-Apelin EV) is an engineered extracellular vesicle (EV) therapeutic developed by ShiftBio for the treatment of pulmonary arterial hypertension (PAH). The platform utilizes interferon-induced transmembrane protein 3 (IFITM3) as a type II transmembrane protein scaffold to orient the apelin peptide on the EV surface with its C-terminus fully exposed, preserving its critical binding interface. To enhance lesion-specific targeting, the EV is dual-engineered with the PAH-targeting peptide CARSKNKDC (CAR), which selectively binds to heparan sulfate overexpressed on PAH endothelial cells. Apelin-EV acts as an agonist of the apelin receptor (APJ/APLNR), promoting vascular homeostasis, reversing pathological vascular remodeling, and improving cardiac function.
- Other names
- Apelin delivered via EV platformCAR-Apelin EVCAR-Apelin EVsCAR-Apelin-EVCAR-Apelin-EVs
02
Targets
APLNR (Apelin receptor)HS (Heparan sulfate)
Beyond the preview
Go deeper on Apelin-EV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apelin-EV.